Last updated: 2026-09-09 04:54:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
XBiotech Inc. (XBIT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.18, with a market capitalisation of $67.07M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.09 to $3.44. This page covers its latest market performance, valuation, price trends and company information.
$67.07M | |
$2.20 | |
$32.50 | |
$2.09 | |
-- | |
43.41K | |
40.03K | |
-- | |
$3.44 | |
$2.09 | |
-- | |
-- |
XBiotech Inc. (XBIT) last closed at $0.00 as of 2026-09-08 23:31:00, -- from the previous close of $0.00.
During the latest regular trading session, XBIT traded between $2.09 and $32.50, with a volume of 43.41K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, XBiotech Inc. (XBIT) moved from $2.30 to $2.18, representing a decline of 5.22% ($0.12).
The stock traded between $2.18 and $2.33 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 92.56 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 6.7%
XBIT is currently trading at $2.18, placing it 6.7% of the way from its 52-week low of $2.09 to its 52-week high of $3.44. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 87 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of XBiotech Inc. (XBIT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.